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Abstract
Background: Bacterial resistance to antibiotics is thought to develop only in the presence of antibiotic pressure. Here we
show evidence to suggest that fluoroquinolone resistance in Escherichia coli has developed in the absence of
fluoroquinolone use.
Methods: Over 4 years, outreach clinic attendees in one moderately remote and five very remote villages in rural Guyana
were surveyed for the presence of rectal carriage of ciprofloxacin-resistant Gram-negative bacilli (GNB). Drinking water was
tested for the presence of resistant GNB by culture, and the presence of antibacterial agents and chloroquine by HPLC. The
development of ciprofloxacin resistance in E. coli was examined after serial exposure to chloroquine. Patient and laboratory
isolates of E. coli resistant to ciprofloxacin were assessed by PCR-sequencing for quinolone-resistance-determining-region
(QRDR) mutations.
Results: In the very remote villages, 4.8% of patients carried ciprofloxacin-resistant E. coli with QRDR mutations despite no
local availability of quinolones. However, there had been extensive local use of chloroquine, with higher prevalence of
resistance seen in the villages shortly after a Plasmodium vivax epidemic (p,0.01). Antibacterial agents were not found in
the drinking water, but chloroquine was demonstrated to be present. Chloroquine was found to inhibit the growth of E. coli
in vitro. Replica plating demonstrated that 2-step QRDR mutations could be induced in E. coli in response to chloroquine.
Conclusions: In these remote communities, the heavy use of chloroquine to treat malaria likely selected for ciprofloxacin
resistance in E. coli. This may be an important public health problem in malarious areas.
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Introduction
Local patterns of both human and agricultural antibiotic
consumption have been shown to correlate with local rates of
antimicrobial drug resistance for many antimicrobial-pathogen
combinations [1,2]. Thus, in truly remote communities, with little
or no access to antimicrobials and limited interaction with other
populations, rates of antimicrobial resistance should be negligible.
High rates of fluoroquinolone resistance among Gram-negative
bacilli (GNB) have been documented in tropical environments that
have extensive use of fluoroquinolones [3–5], and have spread
from there to the developed world [6]. To our knowledge,
widespread fluoroquinolone resistance has not been previously
documented to occur in the absence of fluoroquinolone use.
Chloroquine, 7-chloro-4-(4-diethylamino-1methylbutylamino)-
quinoline, is extensively used throughout the tropics for its activity
against erythrocytic forms of Plasmodium species. In Guyana, fever
with no obvious anatomic source is empirically treated with
chloroquine until malaria smears have been completed. In most
malarious countries, chloroquine is still an important component
in the treatment of P. vivax [7,8], and despite resistance in P.
falciparum [8], recurrent empiric treatment with chloroquine
several times a year is widespread in the tropics, primarily due
to its low cost [9]. In fact national household surveys in 28 African
countries have shown that an average of 42% of children under 5
years with fever were treated with an antimalarial, and despite its
poor efficacy in African children with P. falciparum, more than 80%
of these reported treatments were with chloroquine [10].
Chloroquine is also used in the developed world in the treatment
of rheumatoid arthritis, and systemic lupus erythematosis [11,12].
Chloroquine inhibits DNA and RNA polymerase activity in vitro
[13], halts the replication of Legionella pneumophila by limiting the
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2727availability of iron necessary for intracellular growth [14], and has
weak antibacterial properties [15] against Salmonella sp. [16] and
Bacillus subtilis [17].
The pharmacore of the fluoroquinolones and chloroquine are
similar (Figure 1). In fact the origins of the quinolone class are
from the use of chloroquine as an antimalarial [18]. A compound
isolated from the commercial preparation of chloroquine was
modified to produce the first marketed quinolone, nalidixic acid
[18,19]. Fluorine was subsequently added to produce the
fluoroquinolones, resulting in both an increase in potency and
spectrum. We hypothesized that the extensive use of chloroquine
in tropical countries could select for fluoroquinolone resistance
among E. coli despite the absence of fluoroquinolone use.
Results
Surveillance cultures
A total of 535 rectal swabs were obtained: 240 in 2002, 152 in
2003 and 143 in 2005 (Table 1). Only 15.4% of individuals
reported antibiotic exposure in the previous five years. No patients
received antibiotics within 30 days of sampling. All participants
denied fluoroquinolone use. In 2003, 30% reported chloroquine
use within the previous 6 months and in 2005, 86% reported
chloroquine use within the previous 2 years.
A total of 30 ciprofloxacin-resistant E. coli isolates were isolated
from specimens of 29 (5.4%) of the 535 participants (Table 1 and
2) (one patient in 2005 carried 2 different isolates), and were from
children (12 of 225 [5.3%]) and adults (17 of 310 [5.5%]) with an
age range of 8 months to 65 years. Resistant isolates were obtained
throughout the study period [8 of 240 (3.8%) in 2002, 16 of 152
(10.2%) in 2003, and 5 of 143 (3.5%) in 2005.
The ciprofloxacin MIC ranged between 2 and .32 mg/mL,
with 26 of 30 E. coli having MIC of .32 mg/mL (Table 2). The
chloroquine MIC ranged between 5,000 and 80,000 mg/mL. By
contrast, the chloroquine MIC of susceptible E. coli isolated from
Guyana and Canada ranged between 625 and 1,200 mg/mL.
PFGE typing identified 24 distinct strains among the 30 isolates
(Table 2).
All ciprofloxacin resistant isolates had mutations in parC and
gyrA commonly associated with fluoroquinolone resistance
(Table 2). No qnrA/B genes and no evidence of an active efflux
system were identified. No QRDR mutations were found among
ciprofloxacin-susceptible E. coli isolated from the same patient
population.
Clinical correlates of ciprofloxacin resistance
Non-Bartica village results. 4.8% of patients in the non-
Bartica villages carried ciprofloxacin-resistant E. coli. In the non-
Bartica villages (but not in Bartica) there was a dramatic increase
in number of P. vivax cases between May and December 2002. The
incidence of P. vivax rose from a baseline of 4.97 cases/1000
persons/month (standard deviation [SD]=2.4/1000) to 68.0
cases/1000 persons/month (SD=23.4/1000) an increase of
1,270% (2 tailed p value,0.0001) (CI for the change 57.3–68.7/
Figure 1. A comparison of the chemical structures of ciprofloxacin (A) and chloroquine (B).
doi:10.1371/journal.pone.0002727.g001
Table 1. Demographics of the study population.
Demographics 2002 2003 2005 Total
Number of patients screened 240 152 143 535
Age Group
Children ,17 years (%) 105 (43.8) 63 (41.4) 57 (39.8) 225 (42.1)
Adults 17–65 years (%) 124 (51.7) 75 (49.3) 76 (53.3) 275 (51.4)
Elderly .65 years (%) 11 (4.6) 14 (9.2) 10 (6.9) 35 (6.5)
Sex
Number of males (%) 98 (40.8) 72 (47.5) 62 (43.6) 232 (43.3)
Number of females (%) 142 (59.2) 80 (52.5) 81 (56.6) 302 (56.4)
Village of residence (%)
Bartica 0 24.8 7.7 10.8
Remote villages
Jawalla 6.0 9.2 17.5 10.9
Kako 25.0 24.1 6.3 18.5
Kamarang 23.9 41.8 19.6 28.4
Phillipai 27.7 0 1.4 9.6
Waramadong 17.4 0 42.6 20
Quebanang 0 0 5.5 1.8
Fluoroquinolone resistant E.coli
(%)
8 (3.8) 16 (10.2) 5 (3.5) 5.4
Prior antibiotic use (%) 23 (9.6) 28 (18.4) 26 (18.1) 15.4
Prior chloroquine use (%) N/A 30.2* 86** NA
N/A=not available/not applicable.
*chloroquine use within the previous 6 months.
**chloroquine use within the previous 2 years.
doi:10.1371/journal.pone.0002727.t001
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1,360 smear confirmed cases of P. vivax were reported in the local
population of 4,362 persons. Total malaria cases (P. vivax+P.
falciparum) rose from 7.37/1000 persons/month to 74.9/1000
persons/month (p,0.0001) [a 916% increase]. This increase in
total cases reflects the increased incidence of P. vivax, as there was
no significant increase in P. falciparum cases at this time. Local
treatment for P. vivax consists of chloroquine and primaquine.
Therefore there was a marked increase in chloroquine use in these
communities during this epidemic.
Multivariable analysis that included only the non-Bartica
samples, revealed year of testing as the only factor significantly
associated with the carriage of ciprofloxacin resistant E. coli
adjusted for age, sex, and previous antibiotic use. This adjusted
analysis demonstrated that among residents of the non-Bartica
villages (n=480), testing shortly after the P. vivax epidemic in
February 2003 (prevalence of resistance [POR]=11/108, 10.2%)
compared to the non epidemic periods of February 2002
(POR=8/240, 3.3%) and February 2005 (POR=4/132, 3.0%)
was significantly associated with a higher risk of ciprofloxacin
resistance (OR=3.83, 95% CI: 1.56–9.40, p=0.003). Similarly,
the crude estimate (unadjusted analysis using only non-Bartica
samples) demonstrated testing in February 2003 compared to the
non epidemic periods of February 2002 and Feb 2005 was still
significantly associated with a higher risk of ciprofloxacin
resistance (OR=3.40, 95%CI:1.46–7.95, p=0.0047).
Crude (unadjusted) analysis including only the non-Bartica
villages did not demonstrate age, sex, previous antibiotic use or
reported chloroquine use (recent or ever) to be associated with
carriage of ciprofloxacin resistant E. coli.
General analysisresults. In the following analysesall patients
(including Bartica patients) were included. In combined year
analysis, all independent variables (i.e. age, sex, residence in
Bartica, year of testing, chloroquine use, use of any anti-malarials,
prior antibiotic use) were assessed for association with ciprofloxacin-
resistantE.coliinmultivariablelogisticregressionanalysis.Inanalysis
using variables collected across all three years (age, sex, prior
antibiotic use, village of residence, year of testing), testing in 2003
(compared to 2002 and 2005 combined), with adjustment for sex,
ever antibiotic use and residence in Bartica, was the only factor
Table 2. Characteristics of ciprofloxacin-resistant E. coli isolated from Guyana.
Strain No. Year Village
Ciprofloxacin
MIC (mg/mL)
Chloroquine
MIC (mg/mL) gyrA gyrB parC parE
XbaI PFGE
type
37 2002 Waramadong 2 2500 S83L – S80I – I
60 2002 Waramadong .32 20,000 S83L/D87N – S80I J
68 2002 Waramadong .32 10,000 S83L/D87N – S80I J
110 2002 Kako .32 80,000 S83L/D87N – S80I – G
119 2002 Kako .32 10,000 S83L/D87N – S80I S458A L
195 2002 Kamarang .32 20,000 S83L/D87N – S80I/E84G – G
212 2002 Jawalla 6 5,000 S83L/D87N – S80I – M
223 2002 Kamarang .32 20,000 S83L/D87N – S80I S458T N
257 2003 Kamarang .32 80,000 S83L/D87N – S80I/E84V – A
261 2003 Kamarang .32 10,000 S83L/D87N – S80I S458A C
263 2003 Kamarang .32 10,000 S83L/D87N – S80I S458A O
268 2003 Kamarang .32 20,000 S83L/D87N – S80I S458A O
287 2003 Kamarang .32 40,000 S83L/D87N – S80I – E
296 2003 Kamarang .32 20,000 S83L/D87N – S80I S458A P
308 2003 Kamarang .32 20,000 S83L/D87N – S80I L416F T
312 2003 Kako .32 10,000 S83L/D87N – S80I S458A E
324 2003 Kako .32 5,000 S83L/D87N – S80I – H
329 2003 Kako .32 80,000 S83L/D87N – S80I S458A P
339 2003 Kako .32 20,000 S83L/D87N – S80I S458A P
362 2003 Bartica .32 10,000 S83L/D87N – S80I – Q
363 2003 Bartica .32 40,000 S83L/D87N – S80I S458A R
369 2003 Bartica 16 5,000 S83L/D87N – S80I – D
371 2003 Bartica .32 40,000 S83L/D87N – S80I S458A S
378 2003 Bartica .32 40,000 S83L/D87N – S80I S458A X
47 2005 Waramadong 4 10,000 S83L – S80I – K
76 2005 Jawalla .32 20,000 S83L/D87N – S80I – B
86 2005 Bartica .32 20,000 S83L/D87N – S80I S458A Y
97 2005 Waramadong .32 40,000 S83L/D87N – S80I S458A C
103 2005 Waramadong .32 10,000 S83L/D87N – S80I – Z
119 2005 Jawalla .32 20,000 S83L – S80I S458A U
doi:10.1371/journal.pone.0002727.t002
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carriage (OR=2.73, 95% CI: 1.16–6.38, p=0.02). None of the
other variables (age, sex, chloroquine use, any-antimalarial use,
residence in Bartica, or previous antibiotic use) were associated with
ciprofloxacin-resistant E. coli carriage.
A crude (unadjusted) analysis also did not demonstrate any
association between individual reported chloroquine use (ever, or
within the past 6 months) or previous antibiotic use, and carriage
of ciprofloxacin resistant E. coli. There was no association between
use of traditional medicinal herbs, or cassava ingestion with
quinolone resistance.
Water sample analyses
One of the 24 water samples collected in 2004 yielded a single
isolate of ciprofloxacin-resistant E. coli (MIC of 32 mg/mL) isolated
from Bartica river water. High performance liquid chromatogra-
phy/electrospray ionization/tandem mass spectrometry (LC/MS-
MS) demonstrated that one of 13 samples collected in 2005, river
water from Kamarang, was found to contain chloroquine at a
concentration of 4.7 ng/L. Ciprofloxacin was not detected in any
sample. No antimicrobial activity was detected by microbial
inhibition testing (MIT) in the 13 water samples tested.
Chloroquine selection of fluoroquinolone resistance in
vitro
After serial exposure to chloroquine, three isolates were able to
grow in the presence of ciprofloxacin at 0.032 mg/mL (Table 3).
The ciprofloxacin MIC increased from 0.008 to 0.094 mg/mL in
one isolate and to 0.12 mg/mL in two isolates. Sequencing of the
QRDR regions of gyrA and parC revealed an aspartate-87-tyrosine
mutation in gyrA. Serial exposure to increasing concentrations of
chloroquine resulted in a further increase in the ciprofloxacin MIC
from 0.12 to 6 mg/mL in two of the three strains. Analysis of parC
and gyrA revealed a second mutation in the QRDR of parC
resulting in a change from serine-80-isoleucine. No mutations in
gyrB or parE were detected.
Discussion
To our knowledge this is the first report implicating quinoline
antimalarial use in the development of bacterial quinolone
resistance in the tropics. The resistance mutations that were
found in the Guyanese samples, and selected in vitro by chloroquine
exposure, result in cross resistance to all quinolone antibiotics
(including nalidixic acid, norfloxacin, ciprofloxacin, levofloxacin,
and moxifloxacin).
Antibiotic resistance has become a global crisis as a result of
widespread use of antibiotics in medical and agricultural practice
[3–5]. However, in the remote Amerindian communities of
Guyana there is limited access to antimicrobials. Moreover, there
are geographical barriers limiting travel in and out of this region.
The villages are located in the Guyana highlands, surrounded by
the Pakaraima Mountains and dense tropical rainforest. The
villages themselves are at significant elevation (Kamarang is at
1621 ft). One therefore requires air travel to enter this area
(143.8 mile flight from Bartica), and then boat transport between
communities. These are the headwaters of the Mazzaruni River,
and so contamination of water from higher up in the river does not
occur. This geographic isolation and thus difficulty with travel
leads to financial barriers preventing inhabitants from venturing
beyond the region, and also preventing outsiders from venturing
in. Furthermore as reserved Amerindian communities, there are
political limitations preventing outsiders from travelling into the
region [20–22]. Whether these communities will be able to remain
separate and maintain their culture is unclear due to the fact that
mining companies are now hoping to enter this area [23]. Due to
the isolation of these communities during the course of our study
however, it would be expected that the Amerindians would be
subject to negligible rates of antimicrobial resistance. Despite the
lack of quinolone exposure, we found faecal carriage of E. coli
resistant to ciprofloxacin in 5.4% of this population. A large
intensive care unit survey in the USA done at the same time as our
study, found only 4% of E. coli resistant to ciprofloxacin [24].
We cannot with certainty dismiss the possibility that a few
individuals traveling outside of the region may have been exposed to
fluoroquinolones, and on return, transmitted resistant organisms to
their neighbours. However, this hypothesis is unlikely not only
because of the isolation of these communities, and thus the rarity of
outside travel, but also because the resistant E. coli were primarily
polyclonal and the strains were widely distributed among inhabitants
of different villages. The fact that 24 different clones of quinolone
resistant E. coli were found is evidence that an occasional traveler
would be an unlikely source of the multiple resistant strains and
therefore, there must be a local factor selecting for resistance.
Detailed demographic data on the involved communities, and
regarding the patients presenting to the clinics, and those tested, are
presentedintable1,aswellasAppendixS1,AppendixS2,Appendix
S3 and Appendix S4. The data suggests that the most common
Table 3. In-vitro selection of ciprofloxacin resistance after exposure to chloroquine.
Strain no. Chloroquine Ciprofloxacin gyrA gyrB parC parE
mg/mL mg/mL
271–2029
+ 625 0.008 Wild type Wild type Wild type Wild type
271–2029* 5000 0.094 D87Y – – –
270–3118
+ 625 0.008 Wild type Wild type Wild type Wild type
270–3118* 2500 0.12 D87Y – – –
270–3118** 10,000 6.0 D87Y – S80I –
290–9211
++ 625 0.008 Wild type Wild type Wild type Wild type
290–9211* 2500 0.12 D87Y – – –
290–9211** 12,000 6.0 D87Y – S80I –
*1
st step selection after exposure to chloroquine.
**2
nd step selection after exposure to chloroquine.
doi:10.1371/journal.pone.0002727.t003
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check-up (35%). Fifty three per cent presented with one of the three
most common reasons (check-up, musculoskeletal pains, or request
for family planning). In fact 82% of patients did not have any
infective diagnosis, and only 16% had a bacterial etiology suspected.
Furthermore, none of the patients in our study had received an
antibacterial antibiotic within 30 days of presentation to the clinic.
Therefore we believe that our data reflect the prevalence of
quinolone resistant E. coli in the general population.
Chloroquine is a weakly active antibacterial with a long half life (4
days) that is given frequently and excreted through the bowel; all
factors that may optimize the opportunities to select for bacterial
resistance. In this study, laboratory experiments were able to
demonstrate that chloroquine exposure in-vitro can select for
QRDR mutations in E. coli. Unlike quinine, chloroquine is not felt
to have a natural counterpart. We suspect that chloroquine found in
the drinking water in Kamarang may be the result of contamination
by human waste. This suggests widespread exposure to chloroquine,
even inthe absenceof individual malaria treatment.It is also notable
that chloroquine use within two years of testing was almost universal
and thus identification of an association between chloroquine use
and ciprofloxacin resistance within individuals was not possible.
Nevertheless, resistance in E. coli was highest in the villages that had
recently experienced a dramatic P. vivax outbreak, and the
corresponding increase in chloroquine use may have led to an
increased prevalence of ciprofloxacin-resistant E. coli.S p e c i f i cd a t a
regardingtotalchloroquineuseinthesecommunitiesisnotavailable.
However we inferred a dramatic increase in use in late 2002, as
chloroquine is used for the initial treatment of all cases of suspect
malaria until smears are available, and is then continued for
confirmedcasesP.vivax.Thereforethe1,270%riseinP.vivaxandthe
916% increase in total malaria cases during the epidemic period of
late 2002, implies a dramatic increase in chloroquine use at that
time. It is notable that this data consists of the reported incidence of
smearpositiveandthusTREATEDcases,(notincludingestimatesof
undiagnosed cases)and thereforedoes reflect actual chloroquine use.
Chloroquine levels were measured in the water in a non-
epidemic year (2005) and thus may have been higher at other
times. Although the levels we detected are unlikely to select for
fluoroquinolone resistance, detection of chloroquine in the river,
likely as a result of human waste, may be an indirect measure of
the high volume of chloroquine use in the region. As traditional
dosing for P. vivax used by the medics includes chloroquine 1 g PO
then 500 mg PO 6 hours later, and then 500 mg PO daily62
more days, very high concentrations are achieved in the upper gut,
and these concentrations would exceed those which were used in
vitro to generate resistance. A gradient of concentrations would
likely be generated throughout the intestines and this may facilitate
the emergence of resistance. It is possible that the presence of small
concentrations of chloroquine in the drinking water may have
provided an ongoing selective advantage to ciprofloxacin resistant
E. coli within patient’s intestines, prolonging carriage.
Some local residents may have acquired quinolone resistant E. coli
from exposure to contaminated drinking water. Nevertheless, the
identificationof24distinctisolatesofquinoloneresistantE.coliinthis
population, suggests that a single point source of water contamina-
tion would not be able to explain the multiple circulating strains.
Rather generation of resistant strains is likely occurring in many
different patients’ intestines, with some horizontal transmission
within the community via drinking water contamination.
The potential exposure to both quinolone resistant organisms
and chloroquine itself from human waste contaminated river water
may explain the failure to identify an association between
individual reported use of chloroquine and carriage of quinolone
resistant E. coli. Furthermore the reliability of individual reports of
chloroquine exposure is unknown. Nevertheless the fact that
increased total community chloroquine use (as inferred by testing
in a P. vivax epidemic year versus non-epidemic years) was
significantly associated with prevalence of resistance, is strong
ecological evidence of the association of quinoline use with the
development of quinolone resistance in the community. This
situation is analogous to that seen with antibacterial antibiotics,
where there are very few reports of individual use being associated
with the development of resistance, but the evidence of total
community use leading to increased resistance is more compelling
[1,2]. Indeed, this may be one circumstance in which ecological
data are more useful than individual-level data.
Although no clinical outcomes were impacted in this area by
quinolone resistance, (due to the lack of local quinolone use), we
believe the same phenomenon is likely also occurring in other
malarious communities, and may be leading to a lack of clinical
efficacy of quinolones. This site was particularly interesting to study,
because the lack of the confounding presence of quinolones in the
community allowed us to identify the relationship between
community wide quinoline use for malaria and quinolone resistance
in bacteria.
One limitation of this study is that we failed to rule out the
possibility that other quinoline antimalarials,particularlyprimaquine,
whichtogetherwithchloroquineisthestandardtreatmentregimenin
Guyana for cases of P. vivax, may also be selecting for ciprofloxacin
resistance. Other quinoline and quinoline-like compounds include
quinine, mefloquine, quinidine, halofantrine, lumefantrine, piper-
aquine, pyronaridine, and amodiaquine. Other study limitations
include a limited number and timing of water samples, and failure to
ask about chloroquine exposure in the first year.
This study is the first to identify human carriage of quinolone
resistant organisms in communities that lack any quinolone
exposure. It is also the first to identify antimalarial therapy as a
factor in the development of carriage of quinolone resistant bacteria.
We have reported the selection of E. coli resistance by chloroquine in
this study. A recent report demonstrated that fluoroquinolone
resistancemayresultinanincreaseinmortalityfromE.coliinfections
due to the increased likelihoodof inadequate empirical antimicrobial
therapy [25]. A similar phenomenon likely also occurs in other
organisms treated empirically with quinolones. Indeed persons in
theseveryremoteAmerindianGuyanesecommunitieswerefoundto
carry multiple other quinolone resistant gram negative organisms
including Salmonella (data not shown). Quinolone antibiotics have an
important role in the therapy of many tropical infectious diseases
such as typhoid fever, non-typhoidal Salmonella, Shigella and
enterotoxigenic E. coli infections. They also are important in both
the tropics and in temperate regions in the treatment of gonorrhoea,
urinary tract infections, upper and lower respiratory tract infections,
are becoming increasingly important in the therapy of tuberculosis,
and have widespread use in hospitalized patients. These antibiotics
have excellent oral bioavailability, and do not require refrigeration,
making them a critical component of our antibacterial armamen-
tarium in the tropics, and for these reasons the development of
resistance to these agents has important consequences. As
chloroquine use is widespread throughout the tropics our findings
may represent an important public health problem. In fact, although
P. falciparum chloroquine resistance is widespread, use of quinoline
antimalarials will likely continue, and may increase, as they are used
in artemisinin combination therapy (ACT) [26]. The large scale
recent introduction of these therapies, especially as presently
contemplated for use in mass intermittent presumptive therapy
(IPT) for population wide malaria control [26], could have a
significant impact on the antibacterial efficacy of quinolones.
Resistance from Antimalarials
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malaria treatment/control, our data does not imply that
quinolines should be discontinued from use. However we plan to
carry out further studies is to identify whether some quinolines
may be less likely to induce quinolone resistance than others, and
thus be safer for malaria control programs. Our data also implies
that further investigations regarding the efficacy of quinolone
antibiotics in other regions of high malarial endemicity are
necessary, particularly since many of these areas presently lack
facilities for bacterial culture and sensitivity testing, and thus rely
on empiric treatment. Furthermore our data adds impetus to
programs that lead to the primary prevention of malaria, such as
vector control, and the development of vaccine programs, in order
to reduce the need for widespread quinoline chemotherapy.
Methods
Setting
This study was conducted in the isolated Amerindian
communities of north-western Guyana, and the less isolated,
ethnically-mixed Guyanese community of Bartica. Access to the
Amerindian communities is prohibited to non-Amerindians and
requires travel by bush airplane and canoe. These communities
have no pharmacy, and only amoxicillin, TMP/SMX and the
antimalarials chloroquine, quinine, primaquine, and doxycycline
are available via local medics. Interviews with these medics
confirm that quinolones (including non-fluorinated quinolones)
had never been used in this region. All goods imported to these
areas must be registered with the local Amerindian police.
Commercial fertilizers and animal supplements are not available.
Outreach clinics visited these villages for 2 weeks in February of
2002, 2003 and 2005. In 2002, visits were made to Jawalla, Kako,
Kamarang, Phillipai and Waramadong; in 2003 Jawalla, Kako,
Kamarang and Bartica were visited. In 2005, visits were made to
Jawalla, Kako, Kamarang, Waramadong, Quebanang and
Bartica. All villages except Bartica are highly isolated. These
isolated communities are located along the Upper Mazarruni
River, and their drinking and river water is from the Guyanese
Highlands, and not from any other populated centres. In contrast
to the other communities, Bartica can be reached by speedboat,
and has 2 physicians who have occasional access to fluoroquin-
olone antibiotics. Therefore the majority of our analysis was
focused on only the highly remote communities.
Specimen Collection and Transport
Rectal swabs were obtained from consenting individuals
presenting to the clinics, who also provided demographic and
medical information by interview. Swabs were stored in Amies
transport media at ambient temperature during transport to
Canada. In 2004, 24 water samples of 200 ml each were collected
including six tap and four river water samples from Bartica, three
samples from the Kamarang river and one tap water sample from
Kamarang village, three samples of river water each from
Waramadong village and from the Upper Mazaruni River at
Jawalla, and two each from Kako village and Phillipai. In 2005,
two river water samples (200 ml each) were collected from each of
the remote communities visited as well as one tap water sample
from Kamarang. Samples were kept refrigerated during transport.
Background Clinical Information
In addition to basic demographic information (age, sex, village),
individuals who had rectal swabs sampled were asked the following
questions.
(a) Have you ever taken any antibiotics?
(b) If the answer was no then the following question was
asked: Have you taken any medicines for infection or
sickness?
(c) If the answer was yes the following questions were asked:
What antibiotics have you taken? If patients could not
recall the names, then choices of available medications
(amoxicillin/septrin/metronidazole/doxycyline as well
as ciprofloxacin/‘‘cipro’’[which is not locally available])
and the colours of these medications (matched with the
medics’ supplies) were all offered.
(d) When did you take them?
(a) Have you taken any ‘‘bush medicines’’ (the local term for
traditional medicinal herbs)?
(b) If yes, what were they?
(a) Do you eat Casava (a local staple potato)?
(b) Do you drink it fermented (‘‘Kasrik’’?)
(c) Do you eat cassava bread?
(d) If yes, how many times a day do you eat it?
4. In 2003 patients were also asked:
(a) Have you had malaria in the past 6 months?
(b) Have you had vivax or falciparum malaria or both?
(c) Did you receive ia) chloroquine iib) primaquine iiic)
quinine iv d) doxycycline? (each of these medications
colors were was also described to assist memory)?
5. In 2005 Patients were also asked:
(a) Have you had malaria in the past 5 years? Ever?
(b) How many times have you been treated for malaria?
(c) When was the last time you were treated for malaria?
(d) The last time you were treated, did you have vivax or
falciparum or both?
(e) Did you receive chloroquine/primaquine/quinine/doxy-
cycline? (each of these medications colours were was also
described to assist memory)?
Clinical Information Regarding Health Seeking Behaviour
of the Studied Communities
Data on the first 501 patients visiting the clinic in 2005 was
reviewed. Specific identifying patient data was purged prior to
review. Non-nominal demographic data (age, sex, village, as well
as attending physician diagnosis recorded on the clinic chart at the
end of the patients visit) was tabulated.
Isolation and identification of fluoroquinolone resistant E.
coli
On receipt in Canada, rectal swabs were incubated in brain
heart infusion broth at 35uC for 24 h and then cultured onto
MacConkey agar with and without 1 mg/ml ciprofloxacin and
incubated aerobically at 35uC for 24 h. After incubation, Gram-
negative bacilli growing on the ciprofloxacin containing plate were
identified to the species level by the Vitek GNI card (BioMerieux,
Hazelwood, MO). Ciprofloxacin resistance in E. coli was defined as
an MIC $2 mg/mL. Water samples from 2004 were cultured by
filtering 50 mL through a sterile 0.45 mm millipore filter and
incubating the filter in 20 mL brain heart infusion broth overnight
at 35uC. Turbid broths were sub-cultured by spreading a 100 mL
aliquot onto sheep blood (5%) and MacConkey agar, with a 5 mg
1.
2.
3.
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Gram-negative bacilli within the expected zone of inhibition of the
ciprofloxacin disk was streaked to MacConkey agar to obtain a
pure culture.
Broth microdilution susceptibilities were performed for all
Enterobacteriaceae growing on the ciprofloxacin containing plate, or
within the ciprofloxacin zone of inhibition using Vitek GNS cards
(BioMerieux), with confirmation of ciprofloxacin MICs by EtestH
(AB Biodisk).
Characterization of fluoroquinolone-resistant E. coli and
fluoroquinolone susceptible control strains
The QRDR regions of the gyrA, gyrB, parC and parE genes were
amplified as previously described [27,28]. The presence of qnr
genes were examined as described by Jacoby et al [29]. Purified
DNA amplicons were sequenced using a Beckman CEQ8000
capillary sequencer. To determine if energy dependent efflux was
contributing to fluoroquinolone resistance, ciprofloxacin MICs
were measured in the absence and presence of 10 mg/ml reserpine
[30]. A four-fold reduction in MIC in the presence of reserpine
was considered evidence of efflux-mediated resistance. Isolates
were subject to XbaI PFGE [31,32], and typed using the criteria of
Tenover et al [33]. Chloroquine MICs were determined using
broth microdilution [34].
Investigation for potential presence of antimicrobials in
water samples
High performance liquid chromatography/electrospray ioniza-
tion/tandem mass spectrometry (LC/MS-MS) was utilized to
analyze the water samples for the presence of 23 different
antimicrobials including ciprofloxacin and chloroquine [35].
Microbial inhibition testing (MIT) for the detection of antimicro-
bial activity in water was carried out using both Micrococcus luteus
and Bacillus subtilis in agar plates and 2 mL of penase treated water
samples [36].
Chloroquine selection of fluoroquinolone resistance in
vitro
One fluoroquinolone-susceptible E. coli obtained from Guyana
and two Canadian strains (clinical isolates) from the Queen
Elizabeth II Health Sciences Centre, Halifax, Nova Scotia were
screened for gyrA/gyrB and parC/parE mutations, efflux, and qnrA/
B, then inoculated into100 mL Mueller-Hinton broth (MHB)
containing 625 mg/ml of chloroquine and incubated for 24 hours
at 35uC. A 100 ml aliquot was removed and sub-cultured into
MHB containing 1875 mg/ml chloroquine and incubated for
24 hours at 35uC. The inoculum was then replica plated onto
another MHA plate containing 0.032 mg/ml ciprofloxacin. Both
plates were incubated for 24 hours at 35uC. When ciprofloxacin
containing plates displayed visible growth, colonies on the
antibiotic free replica plates were isolated and tested by examining
their susceptibility to ciprofloxacin and chloroquine, and by
amplification and sequencing of the gyrA/gyrB and parC/parE
genes.
First step mutants, selected with chloroquine, were re-exposed to
increasing concentrations of chloroquine in MHB, (up to
16,500 mg/ml), sub-cultured onto MHA containing a corresponding
concentration of chloroquine, and replica plated onto MHA with
andwithout2 mg/mlofciprofloxacin.Asabove,coloniesgrowingon
the ciprofloxacin containing plates had their coordinate colonies on
the ciprofloxacin free media tested by examining their susceptibility
to ciprofloxacin and chloroquine, and by amplification and
sequencing of the gyrA/gyrB and parC/parE genes
Statistical Analyses
All statistical analyses were conducted in SAS 9.1.3 (SAS
Institute Inc., Cary, NC). Odds ratios (OR) and their correspond-
ing 95% confidence intervals (CI) were calculated using uncon-
ditional multiple logistic regression to identify associations between
each potential risk factor and presence of ciprofloxacin-resistant E.
coli in the sample.
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